Promotion of mitochondrial biogenesis by necdin protects neurons against mitochondrial insults

Koichi Hasegawa¹, Toru Yasuda²†, Chinatsu Shiraishi¹, Kazushiro Fujiwara¹, Serge Przedborski³, Hideki Mochizuki² & Kazuaki Yoshikawa¹

Neurons rely heavily on mitochondria for their function and survival. Mitochondrial dysfunction contributes to the pathogenesis of neurodegenerative diseases such as Parkinson’s disease. PGC-1α is a master regulator of mitochondrial biogenesis and function. Here we identify necdin as a potent PGC-1α stabilizer that promotes mitochondrial biogenesis via PGC-1α in mammalian neurons. Expression of genes encoding mitochondria-specific proteins decreases significantly in necdin-null cortical neurons, where mitochondrial function and expression of the PGC-1α protein are reduced. Necdin strongly stabilizes PGC-1α by inhibiting its ubiquitin-dependent degradation. Forced expression of necdin enhances mitochondrial function in primary cortical neurons and human SH-SYSY neuroblastoma cells to prevent mitochondrial respiratory chain inhibitor-induced degeneration. Moreover, overexpression of necdin in the substantia nigra in vivo of adult mice protects dopaminergic neurons against degeneration in experimental Parkinson’s disease. These data reveal that necdin promotes mitochondrial biogenesis through stabilization of endogenous PGC-1α to exert neuroprotection against mitochondrial insults.

¹Laboratory of Regulation of Neuronal Development, Institute for Protein Research, Osaka University, Suita, Osaka 565-0871, Japan. ²Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan. ³Department of Neurology, Pathology and Cell Biology, Columbia University, New York, New York, 10032, USA. †Present address; Department of Human Genetics, National Center for Child Health and Development, Setagaya, Tokyo 157-8535, Japan. Correspondence and requests for materials should be addressed to K.H. (email: hasegawa@protein.osaka-u.ac.jp) or to K.Y. (email: yoshikaw@protein.osaka-u.ac.jp).
Mammalian neurons require high mitochondrial activities to generate a large amount of ATP for their signalling events such as action potential generation and excitatory synaptic transmission. Mitochondria are also involved in neuronal death and contribute to neuroprotection against various detrimental stresses. Furthermore, mitochondrial abnormalities are suggested to contribute to the pathogenesis of neurodegenerative diseases such as Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Huntington’s disease. However, little is known about the regulatory mechanisms of mitochondrial biogenesis in mammalian neurons under physiological and pathological conditions.

The peroxisome proliferator-activated receptor γ coactivator-1 (PGC-1) family, which consists of PGC-1α, PGC-1β and PRC, plays a central role in governing a transcriptional regulatory network for mitochondrial biogenesis and respiratory function. The PGC-1 family transcriptional coactivators enhance the activities of the nuclear respiratory factors NRF1 and NRF2, which induce transcription of many genes encoding mitochondria-specific proteins involved in respiratory chain, mitochondrial DNA transcription/replication and protein import/assembly. PGC-1α is the first identified PGC-1 family member, and its expression and function have been most extensively studied. In non-neuronal cells, expression of PGC-1α is dynamically regulated at the transcriptional and post-translational levels in response to various environmental stimuli such as temperature, nutritional status and physical activity. However, there is limited information on the regulation of neuronal PGC-1α and its involvement in mitochondrial biogenesis.

Necdin is a MAGE (melanoma antigen) family protein originally isolated from neurally differentiated embryonal carcinoma cells. Necdin is expressed in virtually all neurons originally isolated from neurally differentiated embryonal carcinoma cells. Necdin is expressed in virtually all neurons. It is dynamically regulated at the transcriptional and post-translational levels in response to various environmental stimuli such as temperature, nutritional status and physical activity. However, there is limited information on the regulation of neuronal PGC-1α and its involvement in mitochondrial biogenesis.

Necdin is a MAGE (melanoma antigen) family protein originally isolated from neurally differentiated embryonal carcinoma cells. Necdin is expressed in virtually all neurons originally isolated from neurally differentiated embryonal carcinoma cells. Necdin is expressed in virtually all neurons. It is dynamically regulated at the transcriptional and post-translational levels in response to various environmental stimuli such as temperature, nutritional status and physical activity. However, there is limited information on the regulation of neuronal PGC-1α and its involvement in mitochondrial biogenesis.

**Results**

**Necdin promotes neuronal mitochondrial biogenesis.** We then examined whether mitochondrial amounts and activities are reduced in necdin-null neurons. The levels of mitochondrial DNA (D-loop) and the mitochondrial marker Mitotracker Green FM, which localizes to mitochondria regardless of mitochondrial membrane potential, were reduced by 46% and 31%, respectively, in necdin-null neurons (Fig. 1e,f). The levels of oxidative phosphorylation complexes I–V (CI–CV) subunits were also significantly reduced in necdin-null neurons by 85% (CI, NDUF8), 61% (CII, SDHB), 36% (CIII, UQCRCC2), 78% (CIV, MTCO1) and 47% (CV, ATP5A) (Fig. 1f,g). These results suggest that endogenous necdin promotes mitochondrial biogenesis in cortical neurons.

We determined the effect of necdin on mitochondrial metabolic activity in primary cortical neurons using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT), a tetrazolium dye metabolized into water-insoluble formazan mainly in mitochondria. Necdin-null primary neurons exhibited normal morphology, but contained reduced MTT-formazan deposits (Fig. 2a). In quantitative MTT assay, MTT-formazan levels in necdin-null neurons decreased by 41% in the conditions where cellular damage was absent as assessed by lactate dehydrogenase (LDH) release (Fig. 2b). We further analysed oxidative phosphorylation complex I activity in primary cortical neurons by immunocapture assay. Complex I activity was reduced in necdin-null neurons by 60% (Fig. 2c,d). Cellular ATP levels were also significantly reduced in necdin-null neurons, but not in necdin-null neural progenitor cells (NPCs), indicating that necdin promotes the mitochondrial activity predominantly in differentiated neurons (Fig. 2e). We then examined whether mitochondrial membrane potential is reduced in necdin-null neurons. The levels of chloromethyl-X-rosamine, a mitochondrial membrane potential-dependent fluorescent probe, were reduced by 28% in necdin-null neurons (Fig. 2f).

PGC-1α serves as a master regulator of mitochondrial biogenesis in mammalian cells. Because we found no significant change in PGC-1α expression at the mRNA level in necdin-null neurons, we analysed the expression of PGC-1α at the protein level using a novel antibody raised against mouse PGC-1α (PGCAN) (Supplementary Fig. 1). In NPCs and cortical neurons, PGC-1α was detected as a major 128-kDa band by western blotting, and wild-type cortical neurons expressed higher PGC-1α levels than wild-type NPCs and necdin-null cortical neurons (Fig. 2g). Furthermore, the expression level of PGC-1α in necdin-null neurons was 55% of the wild-type control level (Fig. 2h,i). We then analysed the expression of the PGC-1α...
protein in various tissues at embryonic day 14.5 (E14.5) by western blotting (Fig. 2j). PGC-1α was clearly detected in the brain, slightly in the skeletal muscle (gastrocnemius) and hardly detectable in the heart and liver. ATP levels in the brain and muscle, where necdin was highly expressed, were significantly lower in necdin-null mice than in wild-type mice at E14.5.

Figure 1 | Necdin promotes the expression of mitochondria-related genes in primary cortical neurons. (a) Gene expression profiling of primary cortical neurons prepared from wild-type and necdin-null mice at E14.5 was performed using DNA microarrays. Enriched gene ontology terms of genes whose expression decreased (>20% at \( P < 0.05 \)) in necdin-null cortical neurons. \( P \) value cutoff (yellow line), 1.3 \( = - \log_{10}(0.05) \). (b) Clustered mitochondrion-related genes whose expression changed significantly \( (P < 0.05) \) between wild-type (WT) and necdin-null (knockout; KO) neurons (yellow, up; blue, down; \( n = 3 \)). Full data are in Supplementary Table 1. (c) Expression levels of mitochondria-related genes and mitochondrial biogenesis-regulatory genes in cortical neurons were determined by qRT–PCR (\( n = 3–6 \)). (d) D-loop DNA (mtDNA) levels were measured by qRT-PCR and normalized to nuclear gene \( Rplp0 \) levels (\( n = 4 \)). (e) MitoTracker Green FM (MT Green) fluorescence levels were quantified by fluorescence-activated cell sorting analysis (\( n = 4 \)). Mean fluorescence intensity: 367 (WT); 268 (KO). (f) Expression of oxidative phosphorylation complexes I–V subunits was analysed by immunoblotting using antibodies against the enzyme subunits indicated (f), and these bands were quantified by densitometry (\( n = 4 \)) (g). Data represent means ± s.e.m.; *\( P < 0.05 \), **\( P < 0.01 \), ***\( P < 0.005 \), NS, not significant at \( P > 0.05 \); Student’s \( t \)-test.
The brain levels of PGC-1α were the highest at E14.5 and postnatal day 0 (P0), and reduced markedly at adult stages (Fig. 2l). Expression levels of MTCO1 and necdin were the highest at E14.5 and decreased during postnatal development. Necdin-null mice had lower levels of PGC-1α and MTCO1 than wild-type mice throughout brain development. Interestingly, ATP levels in the brain also decreased sharply during development (<10% and <1% of the E14.5 level at P0 and 17 months, respectively) and were significantly reduced in the brain of necdin-deficient mice (Fig. 2m). We further examined the effect
of necdin on mitochondrial degradation in cortical neurons using carbonyl cyanide m-chlorophenyl hydrazone, a mitochondrial uncoupler, as described previously. There was no difference in the expression levels of the autophagy marker LC3-II between wild-type and necdin-null neurons treated with carbonyl cyanide m-chlorophenyl hydrazone (Supplementary Fig. 2), suggesting that necdin fails to affect mitochondrial degradation.

Necdin and PGC-1α are colocalized in neuronal nucleus. We next investigated the distribution patterns of necdin and PGC-1α in the neocortex by immunohistochemistry. In E14.5 mouse forebrain, virtually all cortical neurons expressed both PGC-1α and necdin (Fig. 3a). Most PGC-1α-expressing cells overlapped with necdin-expressing cells in the cortical plate where differentiated neurons are present. PGC-1α and necdin were colocalized in the nucleus of primary cortical neurons as analysed by confocal laser-scanning microscopy (Fig. 3b). Furthermore, fluorescence microphotometry revealed that PGC-1α and MTO1 immunoreactivities were significantly reduced in the neocortex of necdin-null mice (Fig. 3c–e). These reductions were observed in the cortical plate but not in the ventricular/subventricular zone, where undifferentiated neural precursors are present. Western blot analysis revealed that expression of PGC-1α and MTO1 decreased by 46% and 77%, respectively, in necdin-null forebrain extracts (Fig. 3f,g). Tissue ATP levels were markedly reduced in the dorsal cortical area, which contains the cortical plate, of necdin-null mice but not in the ventral area containing undifferentiated cell populations (Fig. 3h). These data suggest that necdin upregulates the protein levels of PGC-1α and MTO1 in the brain in vivo.

Necdin binds and stabilizes PGC-1α. We next examined the interaction between necdin and PGC-1α by co-immunoprecipitation assay. Endogenous PGC-1α was coprecipitated with necdin in forebrain extracts prepared from wild-type mice, but not from necdin-null mice (Fig. 4a). Co-immunoprecipitation assay using transfected HEK293A cells revealed that PGC-1α was coprecipitated with necdin, which was conversely coprecipitated with PGC-1α (Fig. 4b). Remarkably, PGC-1α expression levels in transfected HEK293A cells were markedly increased by coexpression of necdin, suggesting that the PGC-1α protein expressed in HEK293A cells is strongly stabilized in the presence of necdin. Necdin bound to the N-terminal region of PGC-1α in immunoprecipitation assay and in vitro pull-down assays (Fig. 4c–e). We also analysed the subcellular localization of PGC-1α in transfected HEK293A cells by immunocytochemistry (Supplementary Fig. 3). Necdin was colocalized with PGC-1α in the nucleus of co-transfected HEK293A cells, and coexpressed necdin significantly increased nuclear PGC-1α levels. We then examined whether forced expression of necdin and PGC-1α increases mitochondrial biogenesis in HEK293A cells (Fig. 4f). Necdin failed to increase the expression of MTO1 but promoted PGC-1α-mediated MTO1 expression (untransfected control, 1.0 ± 0.2; necdin, 0.9 ± 0.0; PGC-1α, 2.5 ± 0.5; necdin + PGC-1α, 5.8 ± 0.7; control versus PGC-1α, P < 0.05; PGC-1α versus necdin + PGC-1α, P < 0.01, by analysis of variance with Tukey–Kramer post hoc test, n = 3 per each group).

We also examined whether necdin affects the stabilization of PGC-1β, another PGC family member expressed in mammalian cortical neurons, using HEK293A cells expressing necdin and Myc-tagged PGC-1β or Myc-tagged PGC-1α (positive control; Supplementary Fig. 4). PGC-1β, like PGC-1α, was stabilized by necdin, which promoted PGC-1β-mediated MTO1 expression, suggesting that necdin requires these PGC-1 family proteins for promoting mitochondrial biogenesis.

Necdin inhibits ubiquitin-dependent degradation of PGC-1α. To clarify whether necdin inhibits proteolytic degradation of PGC-1α by the ubiquitin-proteasome pathway, we examined the effects of the protein synthesis inhibitor cycloheximide (CHX) and the proteasome inhibitor MG132 on PGC-1α expression levels in transfected HEK293A cells. Necdin markedly increased the PGC-1α level irrespective of the presence or absence of CHX (Fig. 4g) or MG132 (Fig. 4h), indicating that necdin strongly inhibits the degradation of PGC-1α in the proteasome. We then examined the effect of necdin on ubiquitin-dependent degradation of PGC-1α using a PGC-1α E3 ubiquitin ligase. Rnf34 reduced the PGC-1α level, and necdin completely inhibited the reduction (Fig. 4i). In addition, necdin strongly suppressed Rnf34-mediated ubiquitination of PGC-1α (Fig. 4j). Necdin also protected PGC-1α against ubiquitination mediated by Fbxw7, another PGC-1α E3 ubiquitin ligase (Fig. 4k). These data indicate that necdin stabilizes PGC-1α by inhibiting its degradation in the ubiquitin-proteasomal system.

Necdin prevents oligomycin-induced neurodegeneration. To examine whether necdin promotes mitochondrial biogenesis and function, we transferred the mouse necdin gene into primary cortical neurons using lentivirus vectors (LVs). LV-mediated overexpression of necdin increased the PGC-1α levels by 49% and 91% in wild-type and necdin-null neurons, respectively, as compared with the Emerald Green Fluorescent Protein (EmGFP) control levels (Fig. 5a,b). Similarly, necdin overexpression increased the MTO1 levels 2.1- and 2.7-fold in wild-type and necdin-null neurons, respectively (Fig. 5c). We also examined the effects of necdin overexpression on mitochondrial activities in primary cortical neurons. LV-mediated overexpression of necdin increased MTT levels by 43 and 73% in wild-type and necdin-null neurons, respectively (Fig. 5d). Similarly, necdin overexpression increased the ATP levels by 55% and 63% in wild-type and necdin-null neurons, respectively (Fig. 5e). In necdin-null neurons, necdin increased the MTT and ATP levels to those similar to wild-type control levels.

We then examined whether necdin-null cortical neurons are susceptible to oligomycin, a mitochondrial ATP synthase inhibitor. Oligomycin significantly increased apoptosis of necdin-null neurons during the 4–24 h period (Fig. 5f), suggesting that endogenous necdin suppresses oligomycin-induced apoptosis of cortical neurons. In the LDH-based cytotoxicity assay, oligomycin increased the LDH levels by ~50% in wild-type neurons and 2.3-fold in necdin-null neurons under LV-EmGFP-infected conditions (Fig. 5g), indicating that necdin-null neurons are highly susceptible to oligomycin. Remarkably, LV-mediated overexpression of necdin completely protected necdin-null neurons against oligomycin-induced damage. These results indicate that necdin promotes mitochondrial function to prevent oligomycin-induced degeneration of cortical neurons.

Necdin prevents neurodegeneration in experimental PD models. The mitochondrial complex I inhibitor MPP+ (1-methyl-4-phenylpyridine) and its precursor MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) selectively damage dopaminergic neurons and are commonly used for experimental PD models. We first examined whether necdin prevents MPP+ -induced degeneration of SH-SY5Y cells, a human neuroblastoma cell line susceptible to MPP+. LV-mediated overexpression of necdin increased the expression of PGC-1α and MTO1 in SH-SY5Y cells as analysed by immunocytochemistry and western blotting (Fig. 6a,b). Necdin markedly increased the expression levels of PGC-1α 2.3- and 18.4-fold (compared with EmGFP controls) and those of MTO1 9.3- and 8.6-fold (compared with EmGFP
Figure 3 | Necdin and PGC-1α are colocalized in the nucleus of cortical neurons. (a) Forebrain sections were prepared from E14.5 mice and double-immunostained for PGC-1α and necdin. Nuclear DNA was counterstained with Hoechst 33342. Boxed areas in the upper and lower panels are magnified in the lower panels and insets, respectively. Scale bars, 500 μm (upper), 100 μm (lower) and 10 μm (insets). (b) Primary neurons were triply stained for PGC-1α, necdin and DNA, and observed by confocal laser-scanning microscopy. Confocal images with Z-stacks in accessory panels were merged (right). Scale bars, 10 μm. (c) Sox2, βIII-tubulin (βIII-Tub), MAP2, necdin, PGC-1α and MTCO1 in E14.5 mouse cortical region were analysed by fluorescence immunohistochemistry. Scale bars; 500 μm (first) and 50 μm (second). (d,e) Fluorescence intensities of PGC-1α (d) and MTCO1 (e) in the CP and VZ + SVZ areas of wild-type (WT) and necdin-null (KO) E14.5 mice were quantified by fluorescence microphotometry (PGC-1α, n = 4; MTCO1, n = 5; right). Scale bars, 50 μm. (f,g) PGC-1α and MTCO1 in E14.5 mouse cortex extracts were analysed by immunoblotting (f) and quantified by densitometry (g) (n = 4). (h) The cortex of E14.5 mice was manually dissected into the ventral and dorsal parts, and the ATP levels were measured (n = 3). Data represent means ± s.e.m.; **P < 0.01, ***P < 0.005, NS, not significant at P ≥ 0.05; Student’s t-test. CP, cortical plate; CX, cortex; GE, ganglionic eminence; KO, knockout; LV, lateral ventricle; VZ, ventricular zone; VZ + SVZ, ventricular and subventricular zones.
controls) in SH-SY5Y cells in the absence and presence of MPP⁺, respectively. Necdin increased the MITT levels 1.3- and 2.4-fold (compared with EmGFP controls) in the absence and presence of MPP⁺, respectively (Fig. 6c). Similarly, necdin increased the ATP levels in SH-SY5Y cells by 38% and 79% in the absence and presence of MPP⁺, respectively (Fig. 6d). In the cytotoxicity assay, MPP⁺ significantly increased the LDH levels in uninfected and LV-EmGFP-infected SH-SY5Y cells, whereas forced expression of necdin reduced the LDH levels near MPP⁺-untreated levels (Fig. 6e). These results suggest that necdin improves mitochondrial function to reduce MPP⁺-induced damage of SH-SY5Y cells.

We next investigated whether necdin prevents MPTP-induced degeneration of dopaminergic neurons in the substantia nigra (SN) in vivo using necdin-null mice in the C57BL/6j background, which is susceptible to MPTP. Tyrosine hydroxylase-expressing (TH⁺) dopaminergic cells in the SN pars compacta (SNpc) were quantified after MPTP treatment (Fig. 7a and Supplementary Fig. 5a). There was no difference in the number of SNpc TH⁺ cells between wild-type and necdin-null mice without MPTP treatment, whereas SNpc TH⁺ cells in necdin-null mice were significantly reduced in number when treated with MPTP (Fig. 7b,c). The numbers of TH⁺ dopaminergic neurons were reduced throughout the SNpc area of necdin-null mice. This suggests that endogenous necdin in SNpc dopaminergic neurons is neuroprotective against MPTP toxicity.

Because necdin potentially prevents neuronal apoptosis through suppressing the E2F1-Cdc2 and p53-Bax axes, we...
Figure 5 | Necdin prevents oligomycin-induced neurodegeneration of primary cortical neurons. (a) Primary cortical neurons prepared from wild-type (WT) and necdin-null (knockout; KO) mice at E14.5 were infected with LV expressing EmGFP (LV-EmGFP) or necdin (LV-Ndn), and expression of PGC-1α, MTCO1 and necdin was analysed by western blotting. Control, uninfected neurons. (b-e) PGC-1α (b) and MTCO1 (c) levels were quantified by densitometry (n = 4). (d,e) MTT (d) and ATP (e) levels in LV-infected cortical neurons were measured. (f) Oligomycin (OLG)-induced neuronal apoptosis was analysed by Hoechst 33342 staining for condensed or fragmented nuclei at the times indicated (n = 3). Data represent means ± s.e.m.; **P < 0.01; Student’s t-test. (g) LV-infected cortical neurons were treated without (−) or with (+) OLG for 6 h, and released LDH levels were measured. Data represent means ± s.e.m. (n = 3–4; b–e); *P < 0.05, **P < 0.01, NS, not significant at P ≥ 0.05; analysis of variance with Tukey-Kramer post hoc test.

The present study has shown that necdin overexpression increased the PGC-1α level of mitochondrial biosynthesis.

**Necdin deficiency promotes neurodegeneration.** We investigated the neuroprotective effect of endogenous necdin on SN dopaminergic neurons using necdin-null mice. We first analysed the number of TH+ neurons in the SNpc of wild-type and necdin-null mice at their adult (17 weeks old) and late adult (60 weeks old) stages (Fig. 9a). Although there was no significant difference in the number of SNpc TH+ cells between wild-type and necdin-null mice at 17 weeks of age, the number of SNpc TH+ cells was significantly reduced by 15% in necdin-null mice at 60 weeks of age. We then analysed the expression levels of TH, PGC-1α and MTCO1 in the SN by western blotting (Fig. 9b,c). Similar to the results of TH+ neuron counting, the expression level of TH was decreased by 21% in the SNpc of necdin-null mice 60 weeks old (Fig. 9d). Furthermore, the expression levels of PGC-1α and MTCO1 in the SN decreased by 58% and 63%, respectively, in necdin-null mice 60 weeks old, whereas there were no differences in the SN levels of PGC-1α and MTCO1 between wild-type and necdin-null mice 17 weeks old (Fig. 9e,f). On the other hand, PGC-1α and MTCO1 levels in the cortex of necdin-null mice decreased at 17 weeks of age by 66% and 78%, respectively, and at 60 weeks of age by 37% and 67%, respectively. These results suggest that endogenous necdin prevents degeneration of nigral dopaminergic neurons by maintaining the level of mitochondrial biosynthesis.

**Discussion**

The present study has shown that necdin upregulates the expression of neuronal PGC-1α at the post-translational level. In primary cortical neurons and developing brain tissues, the
levels of necdin parallel with those of PGC-1α and the mitochondrial DNA-encoded protein MTCO1. In addition, PGC-1α and MTCO1 levels in the cerebral cortex in vivo are much lower in necdin-null mice than in wild-type mice at adult stages. These results suggest that necdin is an intrinsic positive regulator of PGC-1α-mediated mitochondrial biogenesis. Virus vector-mediated overexpression of necdin in primary cortical neurons and nigral dopaminergic neurons in vivo upregulates the expression of PGC-1α and MTCO1, indicating that endogenous expression levels of those proteins are controllable by exogenous necdin. Thus, necdin is likely to act as a molecular rheostat to control neuronal mitochondrial biogenesis via PGC-1α. We have employed the mitochondrial oxidative phosphorylation inhibitors in combination with viral vector-mediated necdin gene delivery to demonstrate the neuroprotective effects of necdin. The combination of primary cortical neurons and the ATP synthase inhibitor oligomycin showed that necdin-null neurons are highly susceptible to oligomycin-induced apoptosis, which is fully prevented by overexpression of necdin. To investigate the effects of necdin on neurodegeneration in vivo, we have selected nigral dopaminergic neurons, which are highly susceptible to the mitochondrial complex I inhibitor MPTP, a lipophilic protoxin metabolized in glial cells to MPP⁺, which is concentrated in dopaminergic neurons via the dopamine transporter18. Before the analysis of in vivo PD model, we confirmed the toxic effect of the active MPTP metabolite MPP⁺ on SH-SY5Y neuroblastoma cells, a human catecholaminergic cell line that exhibits apoptotic changes in response to MPP⁺ (refs 26,27). Necdin-mediated protection of SH-SY5Y cells against MPP⁺ toxicity led to further demonstrate the neuroprotective effect of necdin on nigral dopaminergic neurons in vivo against MPTP-induced degeneration. These findings implicate that mitochondrial dysfunction-induced neurodegeneration is preventable by enhancing neuronal mitochondrial biogenesis through overexpression of necdin.

The present study clarified that necdin strongly stabilizes PGC-1α by inhibiting its degradation in the ubiquitin-proteasome system. Necdin interacted with PGC-1α via the N-terminal region that contains the PEST (proline, glutamic acid, serine, threonine) sequence, a domain critical for ubiquitin-proteasomal degradation of PGC-1α in the nucleus28,29. Rnf34 (ref. 22), Fbxw7 (ref. 23) and RNF2 (ref. 30) act as PGC-1α E3 ubiquitin ligases. Necdin efficiently suppressed Rnf34- and Fbxw7-mediated proteasomal degradation of PGC-1α, which is fully prevented by overexpression of necdin. To investigate the effects of necdin on neurodegeneration in vivo,
Fbxw7-mediated ubiquitination of PGC-1α. We speculate that necdin forms a stable nuclear complex with PGC-1α in neurons and protects PGC-1α from ubiquitination mediated by these E3 ubiquitin ligases. The N-terminal amino-acid sequences of PGC-1α and PGC-1β are well conserved5, and these PGC-1 family proteins increase mitochondrial density in primary cortical neurons 21. Thus, we infer that necdin protects PGC-1α and PGC-1β against proteasomal degradation to promote their effects on mitochondrial biogenesis in mammalian neurons.

A genome-wide expression study revealed that PGC-1α-regulated genes controlling cellular bioenergetics are under-expressed in SN neurons affected by PD31. PGC-1α-null mutant mice exhibit striatal lesions32, and their SN neurons are highly susceptible to MPTP33. Moreover, PGC-1α overexpression protects SN neurons against neurodegenerative insults34,35. These findings imply that PGC-1α contributes to the resistance of SN dopaminergic neurons against PD-associated neurodegeneration. In contrast to the beneficial effects of PGC-1α, sustained overexpression of PGC-1α in the SN induces degeneration of dopaminergic neurons 36,37. These inconsistent results suggest that control of exogenous PGC-1α expression levels is crucial for the neuroprotective effects. In contrast, AAV-mediated overexpression of necdin increases endogenous PGC-1α protein levels by inhibiting its ubiquitin-proteasomal degradation at the post-translational level. Thus, we speculate that the necdin gene delivery increases the PGC-1α levels in dopaminergic neurons within a physiologically tolerable extent that is sufficient for effective neuroprotection.

Recombinant AAV displays efficient transduction of SN dopaminergic neurons in vivo and has been often used for analysing the pathogenic mechanism of PD and developing therapeutic strategies. For example, AAV-mediated overexpression of α-synuclein, a major structural component of Lewy bodies seen in neurons undergoing degeneration in PD, induces PD-like neurodegeneration38. AAV-mediated overexpression of Parkin, a ubiquitin E3 ligase whose mutations cause recessively inherited early-onset PD39, ameliorates α-synuclein-mediated or MPTP-induced degeneration of dopaminergic neurons25,40. Moreover, AAV-mediated delivery of PARIS (also known as ZNF746), a substrate of Parkin, induces selective dopaminergic neuron loss, which is prevented by AAV-mediated overexpression of Parkin34. Gene therapy for PD using AAV-mediated gene delivery has reached human clinical trials41. Thus, we propose that AAV-mediated necdin gene delivery provides a novel strategy for mitochondrial biogenesis-based neuroprotection in PD.

**Figure 7 | Necdin deficiency enhances MPTP-induced degeneration of dopaminergic neurons in vivo.** (a) TH-expressing (TH+ ) neurons in the SN were analysed by immunohistochemistry (magnified in lower panels). Wild-type (WT) and necdin-null (knockout; KO) 13-week-old mice were injected intraperitoneally without (–MPTP) or with MPTP (+ MPTP) for 5 consecutive days and killed 21 days after injection. Scale bars, 500 μm (upper) and 50 μm (lower). (b,c) SN sections were immunostained for TH, and the number of TH+ neurons in each section of the SNpc (b) and the total number (c) were presented (15 sections per mouse; n = 4–5). Data represent means ± s.e.m.; **P < 0.01, NS, not significant at P ≥ 0.05; analysis of variance with Tukey-Kramer post hoc test.
Prader–Willi syndrome (PWS), a classic genomic imprinting-associated neurodevelopmental disorder\(^1\). The present study has shown that the brain levels of mitochondrial proteins and mitochondrial activities are significantly reduced in necdin-null neurons. These findings raise the possibility that necdin-null neurons affected in PWS have low mitochondrial activities and reduced ATP levels during neuronal development. Motor proteins such as myosin, kinesin and dynein families are powered by ATP hydrolysis and play key roles in neuronal morphogenesis and network formation during brain development.

**Figure 8 | Necdin prevents MPTP-induced degeneration in vivo of dopaminergic neurons in experimental PD.** (a) Schedule of AAV-mediated gene transfer into SN neurons and MPTP treatment. (b) TH\(^+\) dopaminergic neurons were analysed by immunohistochemistry (magnified in lower panels). AAV expressing GFP (AAV-GFP) or human necdin (AAV-NDN) was microinjected into the SN of 13-week-old mice and treated without (–MPTP) or with MPTP (þMPTP). CT, contralateral SN; IP, ipsilateral SN. Scale bars, 500 µm (top panel) and 50 µm (second panel). (c) TH sections were immunostained for TH, and TH\(^+\) neurons in the SNpc were counted (12 sections per mouse; \(n = 3–5\)). (d) Expression of PGC-1α and MTCO1 in SN tissue extracts was analysed by western blotting. (e,f) Expression levels of PGC-1α (e) and MTCO1 (f) were quantified by densitometry and normalized to β-tubulin (β-Tub) levels (\(n = 4–5\)). Data represent means ± s.e.m.; *\(P < 0.05\), **\(P < 0.01\), NS, not significant at \(P > 0.05\); analysis of variance with Tukey–Kramer post hoc test. (g) MPTP-induced behavioural changes of AAV-infected mice were assessed by the pole test. Success rates in three consecutive trials were presented (\(n = 9–11\)). Data represent means; *\(P < 0.05\), **\(P < 0.01\), NS, not significant at \(P > 0.05\); \(\chi^2\)-test.
development. Mice carrying mutated paternal Ndn exhibit a variety of neurodevelopmental abnormalities such as reduced neuron number, impaired neuronal migration and abnormal axon extension in the embryonic brain. Although there is limited information about the neuropathological abnormalities in the PWS-affected brain, earlier studies using magnetic resonance imaging have revealed multiple morphological abnormalities such as ventriculomegaly, reduced sizes of specific areas and differences in grey and white matter volumes in the brain of such as ventriculomegaly, reduced sizes of specific areas and differences in grey and white matter volumes in the brain of patients with PWS. Thus, we speculate that reduced mitochondrial activities in necdin-null neurons contribute, at least in part, to these neurodevelopmental abnormalities seen in PWS.

Our findings suggest that necdin and PGC-1α cooperate to promote mitochondrial biogenesis in various types of neurons and prevent mitochondria-associated neurodegeneration. Necdin-null mice exhibit low expression of the PGC-1α protein in the brain, where the number of nigral dopaminergic neurons is significantly reduced in late adulthood. Necdin is abundantly expressed in spinal cord motor neurons, and their mitochondrial dysfunction causes ALS. PGC-1α is also suggested to contribute to the pathogeneses of ALS. Intriguingly, necdin expression in spinal cord motor neurons of SOD1 G93A mutant mice, an SOD1 gene mutant ALS model, increases significantly at the early presymptomatic stage and decreases at the late symptomatic stage. We speculate that necdin expression is upregulated for neuroprotection at the early stage of neurodegeneration but declines at the advanced stage. A multicohort transcriptional meta-analysis has revealed that necdin expression is specifically diminished in major human neurodegenerative diseases. These findings raise the possibility that necdin is involved in neuronal resistance or resilience against neurodegenerative insults. Thus, gene therapy using virus-vector mediated necdin gene delivery into specific neurons at risk will be a promising avenue for prevention or therapeutic intervention of neurodegenerative diseases. The present findings also warrant further studies on the neuron-specific mechanism of mitochondrial biogenesis and its association with neurodegenerative diseases.

**Methods**

**Ndn knockout mice.** Ndn knockout mice (Ndn+/−/Ko) were generated and maintained as described. Heterozygous male mice (Ndn+−/+−/P) (>25 generations on the ICR background and 20 generations on the C57BL/6J background) were crossed with wild-type (Ndn+/−/+−/P) female mice to obtain Ndn+−/+−/P and Ndn knockout (Ndn−−/−−/P) litters. Genotypes of all mice were analysed by PCR for mutated Ndn loci. C57BL/6J mice were used for demonstrating MPTP-induced neurodegeneration and phenotypes of Ndn knockout mice (13, 17 and 60 weeks of age). The study was approved by the Animal Experiment Committee (Approval No. 24-04-0) and Recombinant DNA Committee (Approval No. 3642) of Institute for Protein Research, Osaka University, and were performed in accordance with national, institutional and the ARRIVE guidelines.

**Cell cultures.** Primary cortical neurons were prepared from the forebrain of ICR mice (Japan SLC) at E14.5 as described. The cortex was dissected and incubated in 0.5 ml of Ca2+/Mg2+-free Hank’s balanced salt solution with 0.05% trypsin for 5 min at 37°C. Tissues were dissociated with 10% fetal bovine serum (FBS) in Dulbecco’s modified eagle medium (DMEM) and centrifuged at 200g for 3 min. Pellets were resuspended in Neurobasal medium (Life Technologies) supplemented with 2 mM l-glutamine, kanamycin/penicillin and B-27 supplement (1:50 dilution, Life Technologies), plated at a density of ~1 × 10^6 cells per cm² in culture dishes, and incubated for 4 days in vitro (DIV) before analyses. For preparation of primary NPCs, dissociated cortical cells were cultured as floating neurospheres in DMEM/F12 (Life Technologies) supplemented with B-27 (1:50 dilution), 20 ng ml⁻¹ epidermal growth factor (PeproTech) and 20 ng ml⁻¹ basic fibroblast growth factor (PeproTech) for 48 h at 37°C under humidified 5% CO₂ conditions. HEK293A cells (Life Technologies) and SH-SY5Y cells (gift from Dr June Biedler, Memorial Sloan-Kettering Cancer Center) were cultured in DMEM containing 10% FBS at 37°C under humidified 5% CO₂ conditions.

**Figure 9 | Necdin deficiency promotes degeneration of dopaminergic neurons in the SN of late adult mice.** (a) TH+ neurons in the SN of wild-type (WT) and necdin-null (knockout; KO) mice at 17 and 60 weeks of age (wks) were analysed by immunohistochemistry. SN sections were immunostained for TH, and the total number of TH+ neurons were presented (15 sections per mouse; n = 3–6). (b,c) Expression of TH, PGC-1α and MTCO1 in SN tissue extracts was analysed by western blotting. Durations of chemiluminescence detection were adjusted for quantification of each protein band in two age groups, and representative blot images of mice at 17 (b) and 60 weeks (c) are presented separately. (d–f) Expression levels of TH (d), PGC-1α (e) and MTCO1 (f) were quantified by densitometry of western blot signals and normalized to β-tubulin (β-Tub) levels (n = 4 each). Values relative to the WT-SN level (=1) in each age group are shown. Data represent means ± s.e.m.; *P < 0.05, **P < 0.005; NS, not significant at P > 0.05; Student’s t-test.
DNA microarray. Total RNA was extracted from primary cortical neurons at 4 DIV, with phenol and guanidine thiocyanate mixture (TRI Reagent, Molecular Research Center). Expression profiling was performed using CodeLink Mouse Whole Genome Bioarray (Applied Microarrays) according to the manufacturer’s protocol. Total RNA (1 μg) was labelled and used for microarray. Array slides were hybridized at 37°C for 18 h, washed, dried and scanned with a microarray scanner (GenePix 4400A, Molecular Devices). The signal intensities were quantified using CodeLink Analysis Software v5.0 (Applied Microarrays). Gene ontology and clustering of microarray data were analysed using Microarray Data Analysis Tool Ver3.2 (Füglen) and Cluster and TreeView programmes.27

Quantitative reverse transcription-PCR. Total RNA was extracted with the guanidine thiocyanate mixture, and contaminating DNA was digested with RQ1 RNase-free DNase (Promega). For qRT–PCR, total RNA (2 μg) was reverse-transcribed to cDNA using Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics). cDNA (10 μg) was used as templates for PCR mixture (Roche LightCycler FastStart DNA MasterPLUS SYBR Green I, Roche Diagnostics) in a real-time PCR system (LightCycler 1.5, Roche Diagnostics). Primers for qRT–PCR are described in Supplementary Table 2.

Mitochondrial DNA/measurements. Total genomic DNA was extracted from cortical neurons at 4 DIV, and mitochondrial DNA content was quantified by real-time PCR with LightCycler 1.5 using D-loop primers (forward, 5′-GGTTGTCCT ACTTTAGGGGCTCA-3′; reverse, 5′-GATTAGGCCCCGCTATACGAT-3′). Ribosomal protein P0 gene Rplp0 (R36B4) primers (forward, 5′-GTGGGTAAT CTCTCCTGGAAG-3′; reverse, 5′-TTTCCGGCATCTAGTGG-3′) were used as a nuclear genome control for normalizing the D-loop level. For determination of mitochondrial mass in neurons, cortical neurons at 4 DIV were incubated with 100 nM MitoTracker Green FM (Life Technologies) at 37°C for 30 min, and analysed by flow cytometry with FACSCalibur (BD Biosciences).

Western blot analysis. Cells or tissues were homogenized with lysis buffer containing 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% IGEPA CA-630 (MP Biomedicals), 10% glycerol and protease inhibitor cocktails (Complete, Roche Diagnostics). The protein concentration was determined by the Bradford method (Bio-Rad). Proteins (2–10 μg per lane) were separated by 10% SDS–PAGE and electroblotted to polyvinylidene difluoride membranes (immobilon, Merck Millipore). The membranes were incubated with primary antibodies against the mitochondrial complex I-V subunits NDUFB8, SDHHR, UQCR2, MTOC1 and ATP5A (total OXPHOS rodent WB antibody cocktail of antibodies, ab101431, 1:500; Abcam), ncdin (NC243, 1:3,000) (ref. 58), β-tubulin (TUB2.1, 1:1,000, Sigma-Aldrich), PGC-1α (1:500, PCGAN), γ-tubulin (GTU-88, 1:1,000, Sigma-Aldrich), nestin (ST-1, 1:500) (ref. 59), MAP2 (1:5,000, Sigma-Aldrich), α-Ⅱ-synuclein (SYBR Green I, Roche Diagnostics) in a real-time PCR system (LightCycler 1.5, Roche Diagnostics). Primers for qRT–PCR are described in Supplementary Table 2.

Complex I activity assay. Complex I activity was measured using an assay kit based on the immunocapture with immobilized anti-Complex I antibodies on nitrocellulose membranes. Non-labelled (diphosphopyridine nucleotide) or [3H]-labelled (diphosphopyridine nucleotide) substrates were incubated with the LDH reaction mixture at room temperature for 30 min, and measured by spectrophotometry at a dual wavelength of 492/690 nm.

Cell lysates (30 μg protein) were used for the assay according to the manufacturer’s protocol. Complex I activity was measured by incubating with NADH and nitrotetrazolium blue. Signals of resulting blue-purple precipitates on the dipstick were analysed by densitometry and quantified using ImageJ 1.44 software.

ATP assay. ATP levels in cell lysates were analysed by luciferase chemiluminescence-based assays (CellTiter-Glo Luminescent Cell Viability Assay kit, Promega) according to the manufacturer’s protocols. Briefly, cell lysates were mixed with CellTiter-Glo Reagent for 2 min by shaking vigorously and settled for 10 min. Luminescence in reaction mixtures was measured with a luminometer (Lumat LB901, Berthold).

Mitochondrial membrane potential assay. For determination of mitochondrial membrane potential in neurons, cortical neurons at 4 DIV were incubated with 100 nM Rhodamine-X rosamine (MitoTracker Red, Life Technologies) at 37°C for 30 min, and analysed by flow cytometry with FACSCalibur (BD Biosciences).

Immunohistochemistry. Brain tissues of mouse embryos at E14.5 were fixed with 4% paraformaldehyde in phosphate buffer (pH 7.4) overnight and cryoprotected by immersion in 20% sucrose overnight. Frozen 12-μm-thick sections were mounted with primary antibodies at 4°C overnight and fluorescent dye-conjugated secondary antibodies at room temperature for 60 min. The primary antibodies used were rabbit polyclonal antibodies against PGC-1α (PGC1α, 1:500), MTCO1 (ab14705, 1:200, Abcam), MTCO1 and ATP5A (total OXPHOS rodent WB antibody cocktail of antibodies, ab110413, 1:500, Abcam), necdin (NC243, 1:3,000) (ref. 58), α-Ⅱ-synuclein (SYBR Green I, Roche Diagnostics) in a real-time PCR system (LightCycler 1.5, Roche Diagnostics). Primers for qRT–PCR are described in Supplementary Table 2.

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10943 | www.nature.com/naturecommunications
SDS–PAGE and detected by western blotting. PGC-1α expression vector was constructed by subcloning cDNA encoding full-length mouse PGC-1α and PGC-1β (gifts from Dr Akira Nakazato, Kyoto University) into pcDNA3.1+ and 6Myctagged pcDNA3.1+. cDNAs encoding PGC-1α deletion mutants of amino acids 1–200 (N-terminal), 201–400 (transcriptional repression), 401–550 (transcriptional activation) and 551–797 (C-terminal) were generated using synthetic oligonucleotide primers and subcloned into the expression vector.

Co-transfection assays. HEK293A cells were transfected with combinations of expression vectors by the calcium phosphate method and collected after 24 h. For CHX treatment, transfected HEK293A cells were incubated with DMEM/10% FBS containing 500 μM CHX (Sigma-Aldrich) for 60 min. HEK293A cells were transfected with combinations of cDNAs and treated with 10 μM MG132 (Peptide Institute) for 3 h before harvest. For PGC-1α ubiquitination assay, full-length cDNAs encoding the PGC-1α E3 ubiquitin ligases Rnf34 (NM_030564) and Fbxw7 (NM_080842) were cloned from E14.5 mouse forebrain cDNAs used as a PCR template, sequenced, attached with the V5-encoding sequence at the 3′-end, and subcloned into pcDNA3.1+. Proteins were immunoprecipitated with anti-PGC-1α antibody (PCGCAN,150) and analysed by western blotting.

In vitro binding analysis. Deletion mutants of PGC-1α were subcloned into pMAL-C2 vector to make MBP fusion proteins. MBP-fused mutant proteins were affinity purified with amylose resin, and incubated with His-tagged necdn (200 ng) at 4 °C for 30 min in 0.5 ml of the binding buffer containing 20 mM Tris-HCl, pH 7.5, 200 mM NaCl and 1 mM EDTA as described. After washing, bound His-tagged necdn were eluted with 20 mM maltose and detected by western blotting with anti-necdn antibody. MBP fusion proteins were detected by Coomassie Brilliant Blue staining.

Viral vectors. Recombinant LVs were produced in HEK293FT cells by transfecting SIN vector plasmids and two or three helper plasmids using calcium phosphate method as described. Necdin and EmGFP cDNAs were subcloned into pENTR1A entry vector (Life Technologies) to construct the destination vectors CSII-EF1α-necdn-EmGFP and CSII-EF1α-IREs-EmGFP to make LNV-Ndn and LV-EmGFP, respectively. EmGFP (Life Technologies) was used as an expression indicator and negative control for necdin overexpression. The viral titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. The titer was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of plaques obtained in a 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. All LV titres were determined at least in triplicate. Averaged titres of AAV-NDN and AAV-GFP were ~1.2×10^10 genome copies/ml. AAV serotype-1 vector preparation, pAAV-MCS carrying cytomegalovirus promoter was used as a positive control for transduction efficiency. The titre was measured by serial dilution on HEK293FT cells and calculated as AAV number per ml. The titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV vectors were produced in HEK293FT cells by transfection with pAAVentry vectors and pAAV-MCS vector. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]

where c is the number of infected HEK293FT cells in 2-mm-diameter well, m is the number of dilutions and n is the number of wells in the last step of titration. AAV titre was measured in HEK293FT cells infected in 24-well plates. AAV titre was measured by serial dilution on HEK293FT cells and determined as AAV number per ml. AAV titre was calculated by using the equation: 

\[
\text{titre} = \frac{c}{2^{m-n}} \times 10^{m},
\]
24. Mochizuki, H. et al. An AAV-derived Apha-1 dominant negative inhibitor prevents MPTP toxicity as antiparkinetic gene therapy for Parkinson’s disease. Proc. Natl Acad. Sci. USA 98, 10918–10923 (2001).

25. Yasuda, T. et al. Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 70, 686–697 (2011).

26. Ross, R. A., Spengler, B. A. & Biedler, J. L. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J. Natl Cancer Inst. 71, 741–747 (1983).

27. Fall, C. P. & Bennett, Jr J. P. Characterization and time course of MPP+ -induced apoptosis in human SH-SY5Y neuroblastoma cells. J. Neurosci. Res. 55, 620–628 (1999).

28. Sano, M. et al. Intracellular control of protein stability, subnuclear compartmentalization, and coactivator function of peroxisome proliferator-activated receptor γ coactivator 1α. J. Biol. Chem. 282, 25970–25980 (2007).

29. Trausch-Azar, J., Leone, T. C., Kelly, D. P. & Schwartz, A. L. Ubiquitin proteasome-dependent degradation of the transcriptional coactivator PGC-1α via the N-terminal pathway. J. Biol. Chem. 285, 40192–40200 (2010).

30. Sen, N., Satija, Y. K. & Das, S. PGC-1α, a key modulator of p53, promotes cell survival upon metabolic stress. Mol. Cell 44, 621–634 (2011).

31. Zheng, B. et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci. Transl. Med. 2, 52ra73 (2010).

32. Lin, J. et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1α null mice. Cell 119, 121–135 (2004).

33. St-Pierre, J. et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1α transcriptional coactivator. Cell 127, 397–408 (2006).

34. Shin, J. H. et al. PARIS (ZN746) repression of PGC-1α contributes to neurodegeneration in Parkinson’s disease. Cell 144, 689–702 (2011).

35. Mudo, G. et al. Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cell. Mol. Life Sci. 69, 1153–1165 (2012).

36. Cirillo, C., Lengacher, S., Dusonchet, J., Arbischer, P. & Schneider, B. L. Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function. Hum. Mol. Genet. 21, 1861–1876 (2012).

37. Clark, J. et al. Pgc-1α overexpression downregulates Ptk3x and increases susceptibility to MPTP toxicity associated with decreased Bdnf. PLoS ONE 7, e48923 (2012).

38. Kirik, D. et al. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780–2791 (2002).

39. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605–608 (1998).

40. Yasuda, T. et al. Neuronal specificity of α-synuclein toxicity and effect of Parkin co-expression in primates. Neuroscience 144, 743–753 (2007).

41. Bartus, R. T., Weinberg, M. S. & Samulski, R. J. Parkinson’s disease gene therapy: success by design meets failure by efficacy. Mol. Ther. 22, 487–497 (2014).

42. Hirokawa, N., Niwa, S. & Tanaka, Y. Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. Neuron 60, 610–638 (2010).

43. Gerard, M., Hernandez, L., Wevrick, R. & Stewart, C. L. Disruption of the mouse necdin gene results in early post-natal lethality. Nat. Genet. 23, 199–202 (1999).

44. Muscatelli, F. et al. Disruption of the mouse Necdin gene results in hypothalamic and behavioral alterations reminiscent of the human Prader-Willi syndrome. Hum. Mol. Genet. 9, 3101–3110 (2000).

45. Pagliardini, S., Ren, J., Wevrick, R. & Greer, J. L. Developmental abnormalities of neuronal structure and function in prenatal mice lacking the Prader-Willi syndrome gene necdin. Am. J. Pathol. 167, 175–191 (2005).

46. Kuwako, K. et al. Disruption of the paternal necdin gene diminishes TrkA signaling for sensory neuron survival. J. Neurosci. 28, 7090–7099 (2005).

47. Kuwajima, T., Nishimura, I. & Yoshikawa, K. Necdin promotes GABAergic neuron differentiation in cooperation with Dlx homeodomain proteins. J. Neurosci. 26, 5383–5392 (2006).

48. Kuwajima, T., Hasegawa, K. & Yoshikawa, K. Necdin promotes cholinergic neuron differentiation in cooperation with Dlx homeodomain proteins. J. Neurosci. 26, 5383–5392 (2006).

49. Miller, N. L., Wevrick, R. & Mellon, P. L. Necdin, a Prader-Willi syndrome candidate gene, regulates gonadotropin-releasing hormone neurons during development. Hum. Mol. Genet. 18, 248–260 (2009).

50. Yamada, K., Matsuzawa, H., Uchiyama, M., Kwee, I. L. & Nakada, T. Brain developmental abnormalities in Prader-Willi syndrome detected by diffusion tensor imaging. Pediatricts 118, e442–e448 (2006).